Brunei vs Mexico: Statin use vs. average non-HDL cholesterol levels

Brunei
3.8
in 2018
Mexico
3.8
in 2018
Brunei rank
6th
Mexico rank
6th

Statin use vs. average non-HDL cholesterol levels over time

  • Brunei
  • Mexico
01234198019992018

How they compare

Brunei currently reports 3.8 against 3.8 in Mexico, a difference of 0.

Across all 39 years both countries report, Mexico has been ahead every year.

Brunei ranks 6th and Mexico ranks 6th of 191 countries.

Mexico has averaged higher in every one of the 4 decades both report.

Head to head by decade

Decade Brunei Mexico Difference Ahead
1980s 3.76 3.9 0.14 Mexico
1990s 3.7 3.9 0.2 Mexico
2000s 3.77 3.89 0.12 Mexico
2010s 3.8 3.8 0

Averages of every year both report within each decade.

Frequently asked questions

Which has higher statin use vs. average non-hdl cholesterol levels, Brunei or Mexico?
Brunei, at 3.8 against 3.8 in Mexico as of 2018.
What is the difference in statin use vs. average non-hdl cholesterol levels between Brunei and Mexico?
0, with Brunei ahead.
How many years of comparable data are there for Brunei and Mexico?
39 years are reported by both, from 1980 to 2018.
How do Brunei and Mexico rank globally for statin use vs. average non-hdl cholesterol levels?
Brunei ranks 6th and Mexico ranks 6th of 191 countries.
Where does this data come from?
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.